1. Home
  2. CRVL vs JAZZ Comparison

CRVL vs JAZZ Comparison

Compare CRVL & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRVL
  • JAZZ
  • Stock Information
  • Founded
  • CRVL 1987
  • JAZZ 2003
  • Country
  • CRVL United States
  • JAZZ Ireland
  • Employees
  • CRVL N/A
  • JAZZ N/A
  • Industry
  • CRVL Specialty Insurers
  • JAZZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRVL Finance
  • JAZZ Health Care
  • Exchange
  • CRVL Nasdaq
  • JAZZ Nasdaq
  • Market Cap
  • CRVL 5.3B
  • JAZZ 6.1B
  • IPO Year
  • CRVL 1991
  • JAZZ 2007
  • Fundamental
  • Price
  • CRVL $115.09
  • JAZZ $102.78
  • Analyst Decision
  • CRVL
  • JAZZ Strong Buy
  • Analyst Count
  • CRVL 0
  • JAZZ 13
  • Target Price
  • CRVL N/A
  • JAZZ $187.15
  • AVG Volume (30 Days)
  • CRVL 136.9K
  • JAZZ 1.6M
  • Earning Date
  • CRVL 05-21-2025
  • JAZZ 04-30-2025
  • Dividend Yield
  • CRVL N/A
  • JAZZ N/A
  • EPS Growth
  • CRVL 18.07
  • JAZZ 41.75
  • EPS
  • CRVL 1.70
  • JAZZ 8.65
  • Revenue
  • CRVL $871,308,000.00
  • JAZZ $4,068,950,000.00
  • Revenue This Year
  • CRVL N/A
  • JAZZ $7.60
  • Revenue Next Year
  • CRVL N/A
  • JAZZ $3.43
  • P/E Ratio
  • CRVL $67.83
  • JAZZ $11.88
  • Revenue Growth
  • CRVL 12.64
  • JAZZ 6.12
  • 52 Week Low
  • CRVL $76.20
  • JAZZ $95.49
  • 52 Week High
  • CRVL $128.61
  • JAZZ $148.06
  • Technical
  • Relative Strength Index (RSI)
  • CRVL 55.83
  • JAZZ 31.87
  • Support Level
  • CRVL $106.02
  • JAZZ $100.42
  • Resistance Level
  • CRVL $119.57
  • JAZZ $104.12
  • Average True Range (ATR)
  • CRVL 4.86
  • JAZZ 6.41
  • MACD
  • CRVL 0.62
  • JAZZ -1.27
  • Stochastic Oscillator
  • CRVL 66.94
  • JAZZ 22.51

About CRVL CorVel Corp.

CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: